Colchicine for prevention of cardiovascular events

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Hemkens, Lars G ^a   Gloy, Viktoria L ^a   Olu, Kelechi K ^a   Nordmann, Alain J ^a   Briel, Matthias ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; CREATINE KINASE; PLACEBO;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE CORONARY SYNDROME; ALOPECIA; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; ENZYME BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GOUT; HAIR LOSS; HEART ARREST; HEART PROTECTION; HUMAN; IN-STENT RESTENOSIS; LONG TERM CARE; MUSCLE CRAMP; MYALGIA; MYOSITIS; NAUSEA; NEURITIS; NEUROPROTECTION; OUTCOME ASSESSMENT; PERICARDITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; VOMITING;

EID: 84940077594     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011047     Document Type: Article

References (27)

1. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Australian and New Zealand Journal of Medicine 1987;17(3):301-4.
2. Carr SC, Farb A, Pearce WH, Virmani R, Yao JS. Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery 1997;122(4):757-63.
3. Cocco G, Chu DC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. European Journal of Internal Medicine 2010;21(6):503-8.
4. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Research & Therapy 2006;8 Suppl 1:S3.
5. Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, et al.Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. Journal of the American College of Cardiology 2013;61(16):1679-85.
6. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al.C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375(9709):132-40.
7. Food and Drug Administration. Department of Health and Human Services. Code of Federal Regulations. Title 21, Volume 5. Part 312 Subpart B - Investigational New Drug Application (IND). Sec. 312.32 IND safety reporting. Revised as of April 1, 2013.
8. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
10. Imazio M, Brucato A, Forno D, Ferro S, Belli R, Trinchero R, et al.Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart 2012;98(14):1078-82.
11. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. New England Journal of Medicine 2013;368(21):2004-13.
13. Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. American Journal of Cardiology 2007;99(6):805-7.
14. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. Journal of the American College of Cardiology 2013;61(4):404-10.
15. Niel E, Scherrmann JM. Colchicine today. Joint, Bone, Spine: Revue du Rhumatisme 2006;73(6):672-8.
16. O'Keefe JH Jr, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. Journal of the American College of Cardiology 1992;19(7):1597-600.
17. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. Journal of Thrombosis and Thrombolysis 2012;33(1):88-94.
18. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
19. Rodnan GP, Benedek TG. The early history of antirheumatic drugs. Arthritis and Rheumatism 1970;13(2):145-65.
20. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64(21):2399-416.
21. Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006190].
22. Shah PK. Mechanisms of plaque vulnerability and rupture. Journal of the American College of Cardiology 2003;41(4 Suppl S):15S-22S.
23. Shah PK. Inflammation and plaque vulnerability. Cardiovascular Drugs and Therapy 2009;23(1):31-40.
24. Terkeltaub RA. Colchicine update: 2008. Seminars in Arthritis and Rheumatism 2009;38(6):411-9.
25. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism 2010;62(4):1060-8.
26. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization, 2011.
27. Yang LP. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout. Drugs 2010;70(12):1603-13.